Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women

Bio2RDF uri

Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women

http://bio2rdf.org/clinicaltrials:NCT00165698

Bio2RDF identifier

NCT00165698

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00165698

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00165698

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

240

http://www.w3.org/2001/XMLSchema#integer

brief summary [clinicaltrials_vocabulary:brief-summary]

To determine the effect ...... comparing with alfacalcidol.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Efficacy and Safety Study on M ...... tmenopausal Osteoporosis Women

http://www.w3.org/2001/XMLSchema#string

clinical result [clinicaltrials_vocabulary:clinical-result]

clinical results for clinicaltrials:NCT00165698 [clinicaltrials_resource:fafa04016514877e8980673857716cf7]

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Bone Mineral Density BMD (Percentage) Change in Lumber Spine After 12 Months Baseline and 12 months [clinicaltrials_resource:9d9672f3252fee1232452850a4f9f52b]

Bone Mineral Density BMD (Percentage) Change in Lumber Spine After 12 Months Baseline and 12 months [clinicaltrials_resource:e107343416c50bec2cf7ee445dd0e045]

Bone Mineral Density BMD (Percentage) Change in Lumber Spine After 12 Months Baseline and 12 months [clinicaltrials_resource:fff9738337ae3f70368089f21c1f6be4]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Bone Mineral Density BMD (Percentage) Change in Lumber Spine After 12 Months Baseline and 12 months [clinicaltrials_resource:6a927c3a8936c9ca21af2beb606f3a76]

Bone Mineral Density BMD (Percentage) Change in Lumber Spine After 12 Months Baseline and 12 months [clinicaltrials_resource:773f3ac00e57d9b302877d9a4d6d4606]

Bone Mineral Density BMD (Percentage) Change in Lumber Spine After 12 Months Baseline and 12 months [clinicaltrials_resource:a044b434932afa03d9290e6e0838956f]

Bone Mineral Density BMD (Percentage) Change in Lumber Spine After 12 Months Baseline and 12 months [clinicaltrials_resource:bf08b6c04ec85580ecedc428025a687b]

Bone Mineral Density BMD (Percentage) Change in Lumber Spine After 12 Months Baseline and 12 months [clinicaltrials_resource:c3f229a42e899616468b67d8fb532d30]

Bone Mineral Density BMD (Percentage) Change in Lumber Spine After 12 Months Baseline and 12 months [clinicaltrials_resource:f34500c81b0b3e2bab169426d9678d6f]

Bone Mineral Density BMD (Percentage) Change in Lumber Spine After 12 Months Baseline and 12 months [clinicaltrials_resource:f3f85def531e61d2e7521bdb9e09ec48]

completion date [clinicaltrials_vocabulary:completion-date]

2007-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Postmenopausal Osteoporosis [clinicaltrials_resource:8f01f9db3eba2b345c7919df6823a8c2]

condition browse [clinicaltrials_vocabulary:condition-browse]

Osteoporosis [clinicaltrials_resource:c9459dc12a29a492919da111f99903cd]

Osteoporosis, Postmenopausal [clinicaltrials_resource:ed920410efae78bc3520ebb6e3fb3ea5]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Osteoporosis [clinicaltrials_resource:c9459dc12a29a492919da111f99903cd]

Osteoporosis, Postmenopausal [clinicaltrials_resource:ed920410efae78bc3520ebb6e3fb3ea5]

country [clinicaltrials_vocabulary:country]

China [clinicaltrials_resource:ae54a5c026f31ada088992587d92cb3a]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00165698 [clinicaltrials_resource:9b6e0b7c5be8323f2b7118eb934281bd]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2005-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

firstreceived results date [clinicaltrials_vocabulary:firstreceived-results-date]

2010-12-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

alfacalcidol [clinicaltrials_resource:08fb5c913eea5ed4ccea62403dd7ff02]

menatetranone [clinicaltrials_resource:74eaa8ad4cc4d5acc42d3ab5fbd3a127]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Alfacalcidol [clinicaltrials_resource:96ddd1314d6e5f9fc8a3df56a4ebf86d]

Menatetrenone [clinicaltrials_resource:a1bb7838cf3ce2cb55f59ddb955a9df8]

keyword [clinicaltrials_vocabulary:keyword]

Postmenopausal

http://www.w3.org/2001/XMLSchema#string

osteoporosis

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2014-07-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Eisai Co., Ltd. [clinicaltrials_resource:c9dcef426be230ef805c498bffa2580c]

location [clinicaltrials_vocabulary:location]

Beijing Hospital [clinicaltrials_resource:a96f7d19cf240f1fdc39897a82a6f2da]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00165698

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Efficacy and Safety Study on M ...... tmenopausal Osteoporosis Women

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

AS-012 (GLA-CHN-05-01)

http://www.w3.org/2001/XMLSchema#string

outcome [clinicaltrials_vocabulary:outcome]

Bone Mineral Density BMD (Percentage) Change in Lumber Spine After 12 Months [clinicaltrials_resource:NCT00165698/outcome/1]

overall official [clinicaltrials_vocabulary:overall-official]

Hong Di [clinicaltrials_resource:4c17a55cc43b3943e5d7d3296e9f61a6]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

China: Food and Drug Administration [clinicaltrials_resource:c7a9e75495ed866768e97b10c53c1472]

participant flow [clinicaltrials_vocabulary:participant-flow]

participant flow for clinicaltrials:NCT00165698 [clinicaltrials_resource:49c5af4bc62ad78d9dfd1df01c5c37bb]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

reported events [clinicaltrials_vocabulary:reported-events]

Reported events for NCT00165698 [clinicaltrials_resource:0dc3bd112a73d5b410a1224509acf95a]

responsible party [clinicaltrials_vocabulary:responsible-party]

Takao Ishii, Asia regulatory affaires, Eisai Co., Ltd. [clinicaltrials_resource:82206c367f6e3f63078da82a2acdf247]

source [clinicaltrials_vocabulary:source]

Eisai Inc. [clinicaltrials_resource:73f65fc9612e17a505f490571aa8adc5]

start date [clinicaltrials_vocabulary:start-date]

2005-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00165698 study design [clinicaltrials_resource:a6e17dc155719d520abde8edbd2d02d1]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00165698

verification date [clinicaltrials_vocabulary:verification-date]

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00165698

http://www.w3.org/2001/XMLSchema#string

title

Efficacy and Safety Study on M ...... tmenopausal Osteoporosis Women

@en